valproic acid has been researched along with Cerebral Infarction in 11 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Male rats underwent middle cerebral artery occlusion for 60 minutes followed by reperfusion for up to 14 days." | 1.38 | Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. ( Chibane, F; Chuang, DM; Fessler, EB; Leeds, P; Leng, Y; Munasinghe, J; Tsai, LK; Wang, Z, 2012) |
| "Given that there is no effective treatment for stroke, HDAC inhibitors, such as VPA, SB, and TSA, should be evaluated for their potential use for clinical trials in stroke patients." | 1.34 | Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. ( Chen, PS; Chuang, DM; Hong, JS; Kim, HJ; Ren, M; Rowe, M, 2007) |
| "In all the patients with cerebral infarction, the current arrows exhibited the similar pattern as the normal subjects." | 1.31 | Cortical functional abnormality assessed by auditory-evoked magnetic fields and therapeutic approach in patients with chronic dizziness. ( Kandori, A; Miyashita, K; Murakami, M; Naritomi, H; Oe, H; Tsukada, K, 2002) |
| "Pretreatment with phenytoin and carbamazepine prevented a reduction of this activity, which, without either treatment, was observed in the cerebral hemisphere exposed to 30-minute ischemia resulting from unilateral middle cerebral artery occlusion." | 1.29 | Effects of the conventional anticonvulsants, phenytoin, carbamazepine, and valproic acid, on sodium-potassium-adenosine triphosphatase in acute ischemic brain. ( Furui, T; Murakami, A, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, S | 1 |
| Joardar, S | 1 |
| Chatterjee, R | 1 |
| Guha, G | 1 |
| Hashmi, MA | 1 |
| Wang, Z | 1 |
| Tsai, LK | 1 |
| Munasinghe, J | 1 |
| Leng, Y | 2 |
| Fessler, EB | 1 |
| Chibane, F | 1 |
| Leeds, P | 1 |
| Chuang, DM | 3 |
| Oe, H | 1 |
| Kandori, A | 1 |
| Murakami, M | 1 |
| Miyashita, K | 1 |
| Tsukada, K | 1 |
| Naritomi, H | 1 |
| Ren, M | 2 |
| Jeong, M | 1 |
| Leeds, PR | 1 |
| Kikuta, K | 1 |
| Takagi, Y | 1 |
| Arakawa, Y | 1 |
| Miyamoto, S | 1 |
| Hashimoto, N | 1 |
| Kim, HJ | 1 |
| Rowe, M | 1 |
| Hong, JS | 1 |
| Chen, PS | 1 |
| Murakami, A | 1 |
| Furui, T | 1 |
| Gnam, W | 1 |
| Flint, AJ | 1 |
| Kehne, JH | 1 |
| Kane, JM | 1 |
| Chaney, SF | 1 |
| Hurst, G | 1 |
| McCloskey, TC | 1 |
| Petty, MA | 1 |
| Senyah, Y | 1 |
| Wolf, HH | 1 |
| Zobrist, R | 1 |
| White, HS | 1 |
| Minato, H | 1 |
| Kikuta, C | 1 |
| Fujitani, B | 1 |
| Masuda, Y | 1 |
| Matsuda, Y | 1 |
| Neshige, R | 1 |
| Endo, C | 1 |
| Abe, M | 1 |
| Kuroda, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa[NCT01233609] | Phase 2 | 90 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52 (NCT01233609)
Timeframe: baseline to week 52
| Intervention | letters read correctly (Mean) |
|---|---|
| Valproic Acid -- Right Eye | -1.4 |
| Valproic Acid--Left Eye | 0.0 |
| Placebo --Right Eye | 0.2 |
| Placebo --Left Eye | 1.3 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | 80.9 |
| Placebo--Left Eye | 115.7 |
| Valproic Acid--Right Eye | 5.3 |
| Valproic Acid--Left Eye | 19.5 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | -122.9 |
| Placebo--Left Eye | -112.0 |
| Valproic Acid--Right Eye | -293.7 |
| Valproic Acid--Left Eye | -237.1 |
Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry) (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridians (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -1.4 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.6 |
Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye. (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridans (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -0.3 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.2 |
11 other studies available for valproic acid and Cerebral Infarction
| Article | Year |
|---|---|
Rare magnetic resonance imaging findings in medium-chain acyl-coenzyme A dehydrogenase deficiency.
Topics: Acyl-CoA Dehydrogenase; Anticonvulsants; Basal Ganglia; Brain; Brain Ischemia; Carnitine; Cerebral I | 2011 |
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.
Topics: Animals; Anticonvulsants; Blotting, Western; Brain Ischemia; Cerebral Infarction; Hypoxia-Inducible | 2012 |
Cortical functional abnormality assessed by auditory-evoked magnetic fields and therapeutic approach in patients with chronic dizziness.
Topics: Acoustic Stimulation; Aged; Anticonvulsants; Auditory Cortex; Auditory Diseases, Central; Brain Mapp | 2002 |
Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction.
Topics: Acetylation; Animals; Behavior, Animal; Caspase 3; Caspases; Cerebral Cortex; Cerebral Infarction; D | 2004 |
Absence epilepsy associated with moyamoya disease. Case report.
Topics: Anticonvulsants; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiography; Cerebral | 2006 |
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Topics: Animals; Anti-Inflammatory Agents; Brain; Brain Ischemia; Butyrates; CD11b Antigen; Cerebral Infarct | 2007 |
Effects of the conventional anticonvulsants, phenytoin, carbamazepine, and valproic acid, on sodium-potassium-adenosine triphosphatase in acute ischemic brain.
Topics: Animals; Carbamazepine; Cerebral Cortex; Cerebral Infarction; Dose-Response Relationship, Drug; Male | 1994 |
New onset rapid cycling bipolar disorder in an 87 year old woman.
Topics: Aged; Aged, 80 and over; Bipolar Disorder; Cerebral Infarction; Female; Humans; Hypothyroidism; Lith | 1993 |
Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties.
Topics: Animals; Anticonvulsants; Cerebral Infarction; Craniocerebral Trauma; Electroshock; Injections, Intr | 1997 |
Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats.
Topics: Animals; Anticonvulsants; Arterial Occlusive Diseases; Body Temperature; Carbamazepine; Cerebral Art | 1997 |
[A case of upper brainstem infarction developing symptomatic narcolepsy after the administration of anti-convulsant drugs].
Topics: Brain Stem; Cerebral Infarction; Electroencephalography; Female; Humans; Magnetic Resonance Imaging; | 1991 |